760 results found
The 29th biannual report
The United Nations (UN) International Day of Persons with Disabilities promotes community awareness, understanding and acceptance of the estimated 1.3 billion people with disability worldwide and to celebrate their achievements.
'We work a lot with families, babies, pregnancy and young people, and our goal is to see them flourish or to do research that can move them towards that trajectory of flourishing and not just always surviving.'
At the request of the Minister for Health and Aged Care, the National Health and Medical Research Council has undertaken a review of gain-of-function research in Australia. The Executive Summary from the review report, and a copy of the full report, is available below.
The NHMRC Corporate Plan 2024-25 presents our strategy for building a healthy Australia, across the strategic themes (purposes) of investment, translation and integrity of health and medical research. The plan also includes our strategic and health priorities, as well as our key activities planned for 2024–25 and over the next few years. The plan describes the operating context in which we work and outlines our performance criteria and targets for the next 4 years.
In conjunction with the Australian Clinical Trials Alliance, we developed the clinical trials competencies to be used in the development of detailed curricula and training courses by universities, Colleges and other registered training organisations*.
The NHMRC Corporate Plan 2020-21 covers the four years to 2023-24. In line with legislated requirements, it identifies major health issues likely to arise, how NHMRC will deal with these issues (including the continuing impact of COVID-19) and our strategy for health and medical research. It also details the key activities NHMRC will undertake to achieve our purposes, and the operating context in which we work, comprising: environment, capability, risk oversight and management, and organisations NHMRC cooperates with to achieve our purposes.
The NHMRC Corporate Plan 2023–24 presents our strategy for building a healthy Australia, across the strategic themes (purposes) of investment, translation and integrity of health and medical research. The plan also includes our strategic and health priorities, as well as our key activities planned for 2023–24 and over the next four years. The plan describes the operating context in which we work and outlines our performance criteria and targets for the next 4 years. The key elements of our Corporate Plan 2023–24 are summarised in the Plan on a Page.
The National Health and Medical Research Council (NHMRC) Corporate Plan 2022–23 presents our national strategy for health and medical research aligned with our three strategic purposes of investment, translation and integrity. The plan also includes our strategic priorities and health priorities and outlines our key activities planned for 2022–23 and over the next four years. In addition, the plan describes the operating context in which we work and our performance criteria and targets for the next four years
The NHMRC Corporate Plan 2021–22 presents our national strategy for health and medical research aligned with our three strategic purposes of investment, translation and integrity. The plan includes updated strategic priorities and health priorities and outlines our planned key activities in 2021–22 and over the next four years. The plan also describes the operating context in which we work and our performance criteria and targets for the next four years.
Project planning The process of developing a guideline can be long and complex — it needs good organisation and planning to be successful
The rescinded National Statement on Ethical Conduct in Human Research (2007) (National Statement (2007), and as updated, consists of a series of guidelines made in accordance with the National Health and Medical Research Council Act 1992.
This information kit is divided into 5 chapters, covering different aspects of the NHMRC Embryo Research Licensing Committee’s activities.
Information for Institutions reporting on compliance against the NHMRC Funding Agreement.